These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 19174086

  • 21. Adalimumab as therapy for fistulizing orofacial Crohn's disease.
    Doherty G, Kalachand R, Patchett S.
    Inflamm Bowel Dis; 2010 Feb; 16(2):184-5. PubMed ID: 19408321
    [No Abstract] [Full Text] [Related]

  • 22. [The cost effectiveness of adalimumab in Crohn's disease (review of foreign pharmacoeconomic studies)].
    Rudakova AV.
    Eksp Klin Gastroenterol; 2011 Feb; (9):113-9. PubMed ID: 22629787
    [No Abstract] [Full Text] [Related]

  • 23. Anti-TNF antibody therapy in Crohn's disease: the risk of a switch.
    Ricart E, Ordás I, Panés J.
    Gut; 2012 Feb; 61(2):169-70. PubMed ID: 22068167
    [No Abstract] [Full Text] [Related]

  • 24. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T.
    Aliment Pharmacol Ther; 2007 Apr 01; 25(7):787-96. PubMed ID: 17373917
    [Abstract] [Full Text] [Related]

  • 25. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS.
    Am J Gastroenterol; 2009 Dec 01; 104(12):3042-9. PubMed ID: 19724267
    [Abstract] [Full Text] [Related]

  • 26. Adalimumab for cutaneous metastatic Crohn's disease.
    Cury DB, Moss AC, Elias G, Nakao A.
    Inflamm Bowel Dis; 2010 May 01; 16(5):723-4. PubMed ID: 19728388
    [No Abstract] [Full Text] [Related]

  • 27. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.
    Jürgens M, Brand S, Filik L, Hübener C, Hasbargen U, Beigel F, Tillack C, Göke B, Ochsenkühn T, Seiderer J.
    Inflamm Bowel Dis; 2010 Oct 01; 16(10):1634-6. PubMed ID: 20027647
    [No Abstract] [Full Text] [Related]

  • 28. Fulminant Crohn's colitis: when only an antibody will do.
    Ng SC, Kamm MA.
    Inflamm Bowel Dis; 2007 Aug 01; 13(8):971-4. PubMed ID: 17427240
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials.
    Huang ML, Ran ZH, Shen J, Li XB, Xu XT, Xiao SD.
    J Dig Dis; 2011 Jun 01; 12(3):165-72. PubMed ID: 21615869
    [Abstract] [Full Text] [Related]

  • 30. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease.
    Hadziselimovic F.
    J Pediatr Gastroenterol Nutr; 2008 Feb 01; 46(2):208-11. PubMed ID: 18223382
    [No Abstract] [Full Text] [Related]

  • 31. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A, Martinsen TC, Waldum HL, Fossmark R.
    Scand J Gastroenterol; 2012 Jun 01; 47(6):649-57. PubMed ID: 22472026
    [Abstract] [Full Text] [Related]

  • 32. Oropharyngeal and proximal esophageal involvement during adalimumab treatment of Crohn disease.
    Nguyen KD, Alexis R, Schwarz SM.
    J Pediatr Gastroenterol Nutr; 2010 Feb 01; 50(2):225-6. PubMed ID: 19841594
    [No Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L.
    Aliment Pharmacol Ther; 2012 Jun 01; 35(12):1397-407. PubMed ID: 22519466
    [Abstract] [Full Text] [Related]

  • 34. Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease.
    Nichita C, Stelle M, Vavricka S, El-Wafa Ali A, Ballabeni P, de Saussure P, Straumann A, Rogler G, Michetti P.
    Digestion; 2010 Jun 01; 81(2):78-85. PubMed ID: 20093835
    [Abstract] [Full Text] [Related]

  • 35. Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland.
    Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N, Nightingale J, Jacyna MR, Gabe SM, O'Connor M, Harris AW, O'Morain C, Ghosh S.
    Eur J Gastroenterol Hepatol; 2010 Mar 01; 22(3):334-9. PubMed ID: 19528808
    [Abstract] [Full Text] [Related]

  • 36. Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study.
    van der Have M, Belderbos TD, Fidder HH, Leenders M, Dijkstra G, Peters CP, Eshuis EJ, Ponsioen CY, Siersema PD, van Oijen MG, Oldenburg B, Dutch Initiative on Crohn and Colitis (ICC).
    Dig Liver Dis; 2014 Oct 01; 46(10):881-6. PubMed ID: 25081843
    [Abstract] [Full Text] [Related]

  • 37. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
    Hinojosa J, Borrás-Blasco J, Maroto N, Rosique-Robles JD, Alos R, Casterá ME.
    Ann Pharmacother; 2008 Jul 01; 42(7):1130-3. PubMed ID: 18492783
    [Abstract] [Full Text] [Related]

  • 38. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
    Triantafillidis JK, Mantzaris G, Karagiannis J, Papavasilliou E, Papatheodoridis G, Fouskas J, Malgarinos G, Gikas A, Papamichael K, Mathou N, Symboulakis E, Karamanolis D.
    Rev Med Chir Soc Med Nat Iasi; 2010 Jul 01; 114(1):85-90. PubMed ID: 20509281
    [Abstract] [Full Text] [Related]

  • 39. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L, Laclotte C, Bigard MA.
    Aliment Pharmacol Ther; 2007 Mar 15; 25(6):675-80. PubMed ID: 17311600
    [Abstract] [Full Text] [Related]

  • 40. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul 15; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.